Stemedica Cell Technologies, Inc., a US company with investment from JZT, started recruiting patients for its Phase II COVID-19 study.
Jiuzhitang Maker received fund support from Daxing District Program for Advancing Transfer and Transformation of Technological Achievements.
China’s first clinical trial treating ischemic stroke with an imported stem cell product was formally launched.
Jiuzhitang Maker was awarded the prize of "Excellent Enterprise Assuming Social Responsibilities in 2020" by Health News.
Jiuzhitang Maker was officially recognized as a company qualified to establish a postdoctoral station.
Jiuzhitang Maker participated in the 2nd Anti-Aging Conference of China at invitation.
A team led by Wang Youguo, Deputy Party Chief and Governor of Daxing District, visited Jiuzhitang Maker.
Jiuzhitang Maker was selected as one of the “Top 50 Most Innovative Biomedical Enterprises in China for 2020”.
Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA approval of its application for a Phase II clinical trial treating COVID-19 patients with MSCs.
A team led by Yang Tingshuang, Party Chief of Mudanjiang, Heilongjiang Province, visited Jiuzhitang Maker.
Stemedica Cell Technologies, Inc., a US company with investment from JZT, reported remarkable benefits in a study using MSCs to treat 8 COVID-19 patients.
Jiuzhitang Maker and Tiantan Hospital signed a Clinical Trial Cooperation Agreement.
Jiuzhitang Maker was included into Daxing government development planning.
A team led by Academician Wu Zuze, dubbed as Father of Hematopoietic Stem Cells, visited Jiuzhitang Maker.
Stemedica Cell Technologies, Inc., a US company with investment from JZT, received US FDA emergency IND approval for using its bone marrow-derived mesenchymal stem cells to treat severe COVID-19 cases.
Jiuzhitang Maker received fund support from Daxing District Program for Better Development of the Healthcare Industry.
Jiuzhitang Maker was included in a government project translating results from COVID-19 prevention and treatment work.
Jiuzhitang Maker’s Investigational New Drug application for MSC product was approved.
Jiuzhitang Maker was awarded the title of “ZGC Gold Seed Enterprise”.
Jiuzhitang Maker received fund support from Beijing Science and Technology Major Project initiative.
all staff of Jiuzhitang Maker moved into the company’s newly constructed Daxing facility.
Jiuzhitang Maker’s Investigational New Drug application for MSC product was accepted by Center for Drug Evaluation of NMPA.
Jiuzhitang Maker was officially awarded the certificate of “National High-tech Enterprise”.
Jiuzhitang-ALTACO International Healthcare Center held a grand opening ceremony in China-Kazakhstan Khorgos Frontier International Cooperation Center.
Jiuzhitang Maker became a full enterprise member of Chinese Society for Cell Biology.
Jiuzhitang Maker was officially awarded Certificate of Zhongguancun High Technology Enterprise.
Jiuzhitang Maker (Beijing) Cell Technology Co., Ltd. signed cooperation agreements with Mexican company Novastem and Kazakhstan company ALTACO respectively, in an effort to co-build internationalized stem cell research platforms.
The M&A Fund initiated by Jiuzhitang achieved new progress in its investment efforts in the stem cells field – Stemedica Cell Technologies, Inc. of which the Fund has holding interests announced positive data from its clinical study on cerebral stroke.
Press Conference of Jiuzhitang Qihang Fund’s Investment in Stemedica Cell Technologies, Inc. & Global Stem Cell Industry Development Summit was successfully held in Beijing.
Stemedica mesenchymal stem cells were approved and listed by Ministry of Health of Kazakhstan as a treatment of acute myocardial infarction.